|
|
|
|
Due to their reduced risk of graft-versus-host disease, enhancing the overall safety profile, gamma delta T cells are suited for a variety of treatments. Explore methods for clinical scale expansion of gamma delta T cells: zoledronic acid activation and anti-CD3/CD28 activation.
|
|
|
|
|
Gamma delta T cells offer a unique approach to cancer immunotherapy. In this comparative study, learn how anti-CD3/anti-CD28 co-activation overcomes industry challenges and enhances lentivirus transduction efficiency, enabling scalable γδ T cell therapy manufacturing.
|
|
|
|
|
The process associated with the manufacture of CAR-T cell therapies presents challenges that immensely impact patient accessibility. Discover an automated workflow that consolidates the critical steps required for transforming T cells into potent CAR-T cell therapies in just 72 hours.
|
|
|
|
|
High-quality recombinant cytokines are essential for robust T cell manufacturing. Learn about the performance of a set of human cell line-produced cytokines when benchmarked against a leading commercial vendor across both serum-containing and serum-free media systems.
|
|
|
|
|
|
|
